Table 2. AXL1717-Treatment, response and survival of patients.

Patient	Dose bid(mg)	# Cycles received	Response1	Survival time2(months)
1	400	13	PD	13
2	400	23	PD	3
3	4004	23	SD	2
4	300	3	PR	15
5	2154	10	SD	20
6	300	10	SD	24
7	300	1	PD	6
8	2154	6	SD	33
9	300	1	PD	3

¹PD = Progressive disease; SD = Stable disease; PR = Partial regression.

²Months from start of AXL1717-treatment.

³Includes one incomplete treatment cycle. A total cycle = 1.2 months.

⁴Starting dose 300 mg bid.